Delivery Order SPE2DB20D2002-SPE2DB24FL81R
Award Date
8/27/24
Potential Completion Date
8/28/24
Potential Value
$32K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $1,263.72 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of May 22, 2025. This contract is not set aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,985.25 contract is a firm fixed-price delivery order for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has an ultimate completion date of November 21, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award, valued at $2,942.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a performance period ending on December 5, 2024. The contract is a Delivery Order and is priced as a Firm Fixed Price. This award is not associated with a set-aside program. The contract is part...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a ceiling value of $10,389.97 and is a Firm Fixed Price Delivery Order. It does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
The federal contract award SPE2DB20D1004|SPE2DB24FNCPR, valued at $12,618.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of September 19, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA...
This federal contract award is to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract, valued at $157,728.00, was awarded by the Defense Logistics Agency (DLA) and has a firm fixed-price delivery order contract type with a period of performance through March 28, 2024. The contract award is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award from the Defense Logistics Agency (DLA) is a Delivery Order valued at $42,124 awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a period of performance through March 2025. There is no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $97,545.40, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This is a firm fixed-price delivery order contract with a completion date of February 28, 2025. The contract was awarded on February 27, 2025 and does not have a set-aside designation, indicating open...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a medical product. The award has a ceiling value of $6,318.60 and is a Firm Fixed Price Delivery Order contract without a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award, valued at $12,102.80, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a medical product, with a completion date of January 29, 2024. This award is not designated as a set-aside contract. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., the parent company. The contract is a...